2023 MASCC/ESMO共识与整合性和非药物疗法相关的抗指南
A Molassiotis1, Mary Lou Affronti2, Mapi Fleury3
1College of Arts, Humanities & Education, University of Derby, Derby, UK. a.molasiotis@derby.ac.uk.
诸如针和渐进性肌肉放松等综合疗法在治疗恶心和吐方面表现有前途. 然而,对于对非药物抗治疗的更广泛建议,需要更多高质量的研究.
科学领域:
- 综合性瘤学是一种综合性瘤学.
- 基于证据的医学是基于证据的医学.
背景情况:
- 恶心和吐是癌症治疗的常见副作用.
- 抗指南需要定期更新,以纳入新的证据.
- 非药物和整合疗法提供潜在的补充方法.
研究的目的:
- 审查关于恶心和吐综合疗法的文献.
- 为了通知MASCC/ESMO 2023抗指南更新.
- 为非药物抗治疗提出建议.
主要方法:
- 确定了12种整合疗法的系统审查和元分析.
- 使用AMSTAR2工具进行了质量评估.
- 通过共识委员会程序制定了建议.
主要成果:
- 分析了39项审查,许多试验显示了方法上的缺陷.
- 对针/电针,基于食物的干预和渐进性肌肉放松 (带有或没有引导图像) 提出了建议.
- 对生,芳香疗法,催眠,音乐疗法和反射疗法的证据不足.
结论:
- 目前对于综合性抗疗法可能有有限的建议.
- 更高质量的试验对于加强建议至关重要.
- 需要进一步的研究来扩大基于证据的非药物选择的范围.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
05:33Author Spotlight: Alleviating Nausea and Vomiting in Pregnancy with Safe and Effective Auricular Acupuncture
Published on: August 4, 2023
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
